Open AccessQuality-adjusted time without symptom or toxicity and quality-adjusted progression-free survival of first-line maintenance niraparib in patients with advanced ovarian cancer
Author(s) -
Pilar Barretina-Ginesta,
Bradley J. Monk,
Sileny Han,
Bhavana Pothuri,
Annika Auranen,
Dana M. Chase,
Domenica Lorusso,
Charles Anderson,
Sophie AbadieLacourtoisie,
Noelle Cloven,
Elena I. Braicu,
Am Amit,
Andrés Redondo,
Ruchit Shah,
Nehemiah Kebede,
Carol Hawkes,
Divya Gupta,
Tatia Woodward,
David M. O’Malley,
Antonio González-Martín
Publication year - 2021
Language(s) - English
Resource type - Conference proceedings
DOI - 10.3802/jgo.2021.32.s1.oo8
Subject(s) - ovarian cancer , oncology , quality (philosophy) , toxicity , medicine , cancer , philosophy , epistemology